Concept
Trial Design
ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor / ROSETTA Lung-02: Pumitamig
"In this phase 2/3 study (NCT06712316), 23 patients with nonsquamous NSCLC were randomly assigned to receive pumitamig 1400 mg or 2000 mg; both groups also received carboplatin (AUC5) plus pemetrexed (500 mg/m2). Another 21 patients were randomly assigned to receive pumitamig 1400 mg or 2000 mg plus carboplatin (AUC6) and paclitaxel (200 mg/m2). All patients across the 4 groups had stage IIIB/IIIC or IV disease and were not previously exposed to systemic treatment.\n\nThe phase 3 portion of the ROSETTA Lung-02 trial is now recruiting for first-line treatment of squamous and nonsquamous-cell NSCLC, Dr Peters said."
Related Ideas
- Safety SignalsASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
- Study DesignASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
- Trial ResultsASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · TRITON: Tremelimumab Plus Durvalumab and Chemotherapy
- TRITON FindingsASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · TRITON: Tremelimumab Plus Durvalumab and Chemotherapy
- Safety OutlookASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · TRITON: Tremelimumab Plus Durvalumab and Chemotherapy
- Safety ProfileASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
- Survival OutcomesASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
- Expert CommentaryASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib